Persones / Equip Humà

Jaume Mora Graupera

Buscador de publicacions

Publicacions

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): . Nº de cites: 1

    [doi:10.3390/cancers16091735]

  • Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM.

    GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma

    INTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Nº de cites: 7

    [doi:10.1002/ijc.34815]

  • Llurba E, Crispi F, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E.

    Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study

    BMJ Open . 14(3): . Nº de cites: 1

    [doi:10.1136/bmjopen-2023-076201]

  • Villasante A, Corominas J, Alcon C, Garcia-Lizarribar A, Mora J, Lopez-Fanarraga M and Samitier J.

    Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model

    Cancers . 16(5): . Nº de cites: 1

    [doi:10.3390/cancers16051060]

  • Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G.

    Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma

    PEDIATRIC BLOOD & CANCER . 71(1): . Nº de cites: 3

    [doi:10.1002/pbc.30717]

  • Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.

    Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

    Cancers . 15(19): . Nº de cites: 9

    [doi:10.3390/cancers15194837]

  • Gomez-Gonzalez S, Llano-Viles J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C.

    EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping

    iScience . 26(9): 107598-107598. Nº de cites: 1

    [doi:10.1016/j.isci.2023.107598]

  • Cristina Larrosa Espinosa, Mora J and Cheung NK.

    Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2

    Cancers . 15(14): . Nº de cites: 7

    [doi:10.3390/cancers15143729]

  • Reinal I, Ontoria-Oviedo I, Selva M, Casini M, Peiró-Molina E, Fambuena-Santos C, Climent AM, Balaguer J, Cañete A, Mora J, Raya Á and Sepúlveda P.

    Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs

    ANTIOXIDANTS . 12(7): . Nº de cites: 1

    [doi:10.3390/antiox12071378]

  • Aschero MR, Castillo H, Baulenas-Farrés M, Resa-Parés C, Jiménez-Cabaco A, Rodriguez E, Monterrubio C, Pérez-Jaume S, Suñol M, Chantada G, Lavarino C, Mora J and Carcaboso AM.

    Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma

    PEDIATRIC BLOOD & CANCER . 70(6): . Nº de cites: 3

    [doi:10.1002/pbc.30318]